The launch of Neurosterix with significant funding and the transfer of preclinical assets and technology platforms to this new venture indicates a major strategic move for Addex. This partnership and the focus on developing treatments for neurological disorders could potentially open up new revenue streams and enhance Addex's market position. The positive impact on Addex's stock price in the short term is likely due to investor optimism about the potential returns from this new venture.